Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 5, 2019Late-breaking clinical trial data demonstrate high rates of primary patency and significantly lower rates of clinically-driven target lesion revascularization for peripheral drug-eluting device portfolio
Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...
-
Nov 5, 2019
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...
-
Oct 23, 2019
"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.
-
Oct 22, 2019
Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.
-
Sep 26, 2019Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after undergoing percutaneous coronary intervention
Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.
-
Sep 18, 2019
Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.
Aug 19, 2019System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.
-
Aug 19, 2019
BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.
-
Jul 24, 2019
"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.
-
Jun 26, 2019Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow
Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.